MedTrace Logo

Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria

NCT01141478 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-10-15

Study results available
· View outcomes & findings →

Summary

This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared to Sorafenib alone will produce the best results for treating patients with Hepatocellular Carcinoma.

Conditions

  • Carcinoma, Hepatocellular

Interventions

RADIATION

Proton Beam Radiotherapy

Fifteen consecutive sessions

DRUG

Sorafenib

400 mg po bid

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Michael deVera, MD · Loma Linda University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-08
Primary Completion
2014-12-26
Completion
2016-06-10
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01141478 on ClinicalTrials.gov